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   ABSTRACT 
 
Background: Tuberous Sclerosis Complex 
(Bourneville’s disease) is genetic disorder with 
autosomal pattern of heritence that affecting 
differentiation sellular in many organ such as 
brain, lungs, cardiac with varible severity. Birth 
incidence is estimated to be 1:6000. The purpose 
of this study was to reported a case of patients 
with Bourneville’s disease (tuberous sclerosis 
complex) in Moewardi Hospital. Also reported 
surveillance and complication in this patient. 
Case Presentation: A male, 18 yearsold, with 
seizures, onset from infancy, tonic secondary 
generalized seizure pattern simultaneously 
throughout the body. Neurologic status exami-
nation found right hemiparese and mental re-
tardation, Encountered in patients with skin 
disorders such as butterfly appearance with facial 
angiofibroma, forehead fibrous plaque dan shar-
green patch. Abnormalities also appeared in the 
oral mucosa as multiple papules. When psych-
ological tests patient had difficulty following 
instructions. Psychiatric examination showed 
moderate lower intelegence. EEG results slow 
waves at left parietal, there is severe electrofisio-
logic abnormality considered structural lesion in 
left parietal. CT showed multiple calcified nodul-
es in subependymal right and left lateral ventri-
cle. MRI showed  atrophy and left sclerotic hip-
pocampus with glosis in sub cortex occipito left 
parietal. To overcome the seizure patients given 
Carbamazepine. There was increasing of trans-
aminase enzim, liver suspect liver angiomyo-
lipoma. 
Conclusion: Based on clinical criteria for definite 
tuberous sclerosis complex patients met the 
criteria. The patients responded positively to 
carbamazepine that reduced seizure frequency. 
But somehow, patient's prognosis is worst. Pre-
sence of intellectual impairment and neuropsy-
chiatric problems is a potential poor epilepsy 
control, and liver disfunction so that the necessa-
ry comprehensive management and surveillance 
involves other disciplines. 
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BACKGROUND 
Tuberous Sclerosis Complex (TSC) or also 
called Bourneville disease is an autosomal 
dominant genetic disease that involves multi-
organ disorders involving the brain, skin, 
kidneys, liver, lungs, heart, and in some cases 
may involve the retina, ginggiva, bone and 
digestive system (Curatolo et al., 2018; 
Krueger et al., 2013; Northrup et al., 2013). 
Sherlock then introduced this syndrome as a 
trier of Tuberous sclerosis with the abbre-
viation EPILOIA (Epi: epilepsy, Loi: Low 
Intelligence, A: Adenoma sebaceum) (De 
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Waele et al., 2015; Sarkar et al., 2016). This 
syndrome is very important in the neurology 
because more than 90% of TSC patients 
develop neurological symptoms such as epi-
lepsy, austism spectrum disorders (ASDs), 
intelligence disorders, sleep disorders, 
behavioral disorders, TSC-related neuropsy-
chiatric disorders (TAND) which cause se-
parate problems in patients and patient 
family(Jülich and Sahin, 2014). 
This genetic disease is rare with an 
increase in the number of events each year. 
The incidence rate is 1: 6,000-100,000 per 
live birth and the prevalence in the popula-
tion reaches 1: 20,000 (Curatolo, 2015; Cura-
tolo et al., 2018; Krueger et al., 2013; North-
rup et al., 2013). This disease is often difficult 
to diagnose due to a variety of phenotypic 
symptoms. It is important for data for the 
Asia Pacific region to be very limited, but in 
studies in Taiwan populations it is stated that 
there are similarities in the distribution of 
phenotypes and mutations with the Cauca-
sian race(Lawson et al., 2014). 
Considering the variety of clinical pre-
sentations and their exposure to many 
organs, as well as the development of diseas-
es that will occur during life, it is necessary to 
establish accurate and early diagnosis, integ-
rated management, and continuous clinical 
monitoring so that they can recognize com-
plications early and proactive management 
so as to reduce mortality and mortality mor-
bidity of patients with tuberous scleosis 
complex. The International Tuberous Sclero-
sis Complex Concensus Conference 2012 
(Northrup et al., 2013) published several re-
commendations for new diagnostic criteria, 
including more comprehensive and sustaina-




Patient with his family come to the Neurology 
clinic of Surakarta Moewardi Hospital with a 
history of seizures. The patient has been 
routinely controlled at the Neurology clinic at 
the Moewardi Hospital in Surakarta since 
September 2014. During this time, the seizur-
es were controlled, the patient has not had 
seizures for the past 11 months. Patients take 
carbamazepin 200 mg twice a day regularly. 
Previously, in early September 2014 the 
patient had experienced epilepticus refracter 
status because at that time the patient did not 
take anti-eplileptic drugs regularly. The 
patient have right hemisphere, the right hand 
is weaker than the right leg. Patients have a 
history of uncontrolled seizures since child-
hood, disappear, arise spontaneously, each 
seizure about 1-2 minutes. The patient 
experiences mental retardation, a develop-
ment that is late compared to children his 
age. Behavior and intelligence of patients 
such as children aged 4 years, until now a 
special school. Patients can be invited to 
communicate even though it is limited. Can 
answer simple questions and can explain 
your own identity. 
Patients have skin disorders such as 
butterfly appearance with angiofibroma facial 
(Figure1), forehead fibrous plaque (Figure2) 
and shargreen patch (Figure3). Abnormaliti-
es also appear in the oral mucosa as multiple 
papules. The histopathological findings 
showed perifollicular fibrosis & dilatation of 
blood vessels, supporting the appearance of 
angiofibroma (Figure4, 5). 
EEG results indicates slow waves at the 
left parietal region, there is severe electro-
physiologic abnormalities considered struc-
tural lesion in the left parietal brain. CT-scan 
showed multiple calcified nodules in sub- 
dependent right and left lateral ventricles 
(figure6), with lateral ventriculomegaly.  
MRI showed atrophy and sclerosis of 
the left hippocampus, hemiatrophy  in left 
hemisphere with glyosis in left perilateral 
ventricular subcortex occipitoparietal region, 
lateral ventriculomegaly with sub ependymal 
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calsificasion (figure7,8). Abdominal ultra-
sound found fatty liver and inguinal lympha-
denopathy. There was an increase in trans-
aminase enzymes, suspected angiomyolipo-











































Figure1. Angiofribrima in regio 
facialis 
Figure 2. Forehead fibrous plaque 
 
Figure 3. Shargreen patch Figure 4. Perifollicular fibrosis and 
dilatation of blood vessels 
Figure 5. Perifollicular fibrosis and 
dilatation of blood zooming 
Figure 6. Nodul Calsificasion 
multiple in subependymal 
lateral ventricle bilateral and left 
ventriculomegaly lateral 
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Summarizing his past history, extensive 
physical signs and investigations, the final 
diagnosis of Tuberous Sclerosis Complex was 
made. He remained was ultimately dis-




It can be concluded from the history of the 
disease, collection of symptoms, a series of 
investigations, and obtained major clinical 
signs that support the diagnosis of tuberous 
sclerosis in accordance with the criteria, 
namely angiofibroma facialis, shargreen 
patch, Subdependent nodules on CT scan, 
cortical tuber on MRI, then clinically erect 
diagnosis of tuberous sclerosis. 
In otherwise, in this patient there is a 
complication that is an increase in trans-
aminase and fatty liver enzymes on ultra-
sound, there is a possibility of angiomyolipo-
ma in the liver. On the other hand, adminis-
tration of carbamazepin has the potential to 
cause hepatotoxicity. It is necessary to moni-
tor liver function periodically. 
Surveillance and management of TSC 
patients who have been diagnosed as definite 
or possible TSCs based on Recommendations 
of the 2012 International that have been 
adjusted for tuberous sclerosis patients in 
this case, so as to reduce morbidity and 
mortality. 
This case study concludes that in this 
patient there are 4 major signs of TSC diag-
nostic criteria, namely: angiofibroma (>3) or 
fibrous cephalic plaque, Shargreen patch, 
cortical diplasia, subodimal nodules from 
clinical manifestations of multiple organ 
systems, including the brain, skin, and liver. 
Comprehensive and continuous mana-
gement of multiorgans that are potentially 
involved is needed in order to properly diag-
nose TSC, so that lifelong supervision, good 
education, and early identification of compli-
cations can be carried out. 
The selection of antiepileptic drugs in 
TSC patients must be done carefully in order 
to achieve maximum synergy with minimal 
side effects. These patients have controlled 
seizures using carbamazepine while continu-
ing to monitor liver function over time. need 
to be considered for the administration of 
sirulimus or everolimus immunosuppres-
sants (mTOR inhibitors) which are the 
recommended first-line therapy (Curatolo et 
al., 2018; De Waele et al., 2015), and are 
included in the BPJS formulary. mTOR in-
hibitors have been shown to reduce the 




Figure 8. Hemiatrophy hemisfer 
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frequency and severity of epilepsy and inhibit 
the development of tuberous slerosis in other 
organs (Curatolo, 2015). 
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